|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
With further analysis of the CCNY levels, there were no differences in age, sex, smoking status, tumor location, histologic subtype, or tumor size, but differences were observed in lymphatic (<i>P</i><0.001) and distant (<i>P</i><0.001) metastases in NSCLC patients.
|
30774378 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Moreover, in a Cox regression analysis, anti-CCNY autoantibody was an independent factor that predicted poor prognosis for postoperative patients with early-stage NSCLC (P = 0.026) as well as for those with distant metastasis (P = 0.012).
|
24167380 |
2013 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We also identified recurrent focal amplification of gene CCNY derived from BFB in two metastatic tumors, but not in primary tumor.
|
28381877 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells.
|
29557391 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our study suggests that CCNY may be useful as a latent tumor marker to facilitate diagnosis and may be an effective indicator of tumor aggressiveness, playing an important role in the prognosis of NSCLC patients.
|
30774378 |
2019 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Furthermore, CCNY mRNA expression positively correlated with histologic types (squamous cell carcinoma vs. adenocarcinomas; P = .048) and with the tumor size (size > 3 cm vs. size ≤ 3 cm; P = .010) in NSCLC.
|
21273179 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the training set, serum CCNY was markedly increased in the NSCLC patients (<i>P</i><0.05) with an integrated area under the curve of 0.751.
|
30774378 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, CCNY mRNA expression positively correlated with histologic types (squamous cell carcinoma vs. adenocarcinomas; P = .048) and with the tumor size (size > 3 cm vs. size ≤ 3 cm; P = .010) in NSCLC.
|
21273179 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These studies suggest that CCNY may be a candidate biomarker of NSCLC and a possible therapeutic target for lung cancer treatment.
|
20596919 |
2010 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Overexpression of cyclin Y in non-small cell lung cancer is associated with cancer cell proliferation.
|
20596919 |
2010 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
We identified several candidates implicating the CDK16/CCNY complex in cytoskeletal dynamics, and we focused on the microtubule-associated protein regulator of cytokinesis (PRC1), an essential protein for cell division that organizes antiparallel microtubules and whose deregulation may drive genomic instability in cancer.
|
30992425 |
2019 |
|
Primary malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The expression status of CCNY in lung cancer and its clinical significance remain unknown.
|
20596919 |
2010 |
|
Primary malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
Hence, the aim of this study was to explore the potential role of CCNY in lung cancer.
|
21273179 |
2011 |
|
Primary malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
CCNY, a novel cyclin family member, plays an increasingly important role in the progression of tumor invasion and metastasis, including lung cancer.
|
30774378 |
2019 |
|
Regional enteritis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
|
Secondary Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
With further analysis of the CCNY levels, there were no differences in age, sex, smoking status, tumor location, histologic subtype, or tumor size, but differences were observed in lymphatic (<i>P</i><0.001) and distant (<i>P</i><0.001) metastases in NSCLC patients.
|
30774378 |
2019 |
|
Squamous cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, CCNY mRNA expression positively correlated with histologic types (squamous cell carcinoma vs. adenocarcinomas; P = .048) and with the tumor size (size > 3 cm vs. size ≤ 3 cm; P = .010) in NSCLC.
|
21273179 |
2011 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The CFP1 and 14-3-3 genes can be used as prognostic markers in patients with GC, but the study is still needed to confirm.
|
31496919 |
2019 |
|
Tuberculosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The levels of anti-CCNY autoantibodies were higher in the sera of the patients with NSCLC than in the sera of the healthy controls (P < 0.001) or the patients with tuberculosis (P = 0.027).
|
24167380 |
2013 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
CCNY, a novel cyclin family member, plays an increasingly important role in the progression of tumor invasion and metastasis, including lung cancer.
|
30774378 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Fisetin decreases TET1 activity and CCNY/CDK16 promoter 5hmC levels to inhibit the proliferation and invasion of renal cancer stem cell.
|
30411496 |
2019 |
|
Ulcerative Colitis
|
0.420 |
GeneticVariation
|
disease |
BEFREE |
Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with ulcerative colitis in our sample collection.
|
18438405 |
2008 |
|
Ulcerative Colitis
|
0.420 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.
|
21297633 |
2011 |
|
Ulcerative Colitis
|
0.420 |
GeneticVariation
|
disease |
BEFREE |
We identified multiple previously unreported or unconfirmed disease associations, including known CD loci (ICOSLG and TNFSF15) and T1D loci (TNFAIP3) that confer UC risk, known UC loci (HERC2 and IL26) that confer T1D risk and known UC loci (IL10 and CCNY) that confer CD risk.
|
20176734 |
2010 |
|
Ulcerative Colitis
|
0.420 |
Biomarker
|
disease |
CTD_human |
Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with ulcerative colitis in our sample collection.
|
18438405 |
2008 |